Three questions to Mario Kuttke, Head of Cell Therapy
1. Do cell therapies represent a breakthrough in cancer treatment? Mario Kuttke: It is really amazing how adoptive cell therapy (ACT), a form of cancer immunotherapy, has evolved so rapidly...
July 27, 2022
No Comments
The race against cancer – targeting Cbl-b in cellular therapy
invIOs’s novel clinical stage lead therapeutic candidate, APN401, combines advances in immune cell therapy and RNA interference methods to treat advanced solid cancers. Immune therapy – hitting new targets Immune...
June 29, 2022
No Comments
Press release: APEIRON shareholders approve new group structure
geared towards enabling innovation and growth invIOs becomes fully separate entity focused on advancing its unique EPiC cell therapy platform and clinical-stage immuno-oncology pipeline Vienna, Austria, 26 April 2022. APEIRON...
April 26, 2022
No Comments
Three questions to Alexander Dohnal, Head of Preclinical Development
1. Ribonucleic acids have for a long time been DNA’s “little sister”. What’s so different between RNA and DNA? Alexander Dohnal: RNA and DNA have a lot in common. Chemical...
April 5, 2022
No Comments
RNA – in the midst of a medical revolution
Ribonucleic acid (RNA) therapies are promising to change the way we treat diseases. From cancer therapies to vaccines and treatments for genetic diseases, the opportunities are almost infinite.
April 5, 2022
No Comments
Press release: invIOs to present at upcoming conferences
Vienna, Austria, 03 February 2022: invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, today announced the participation at three upcoming investor conferences, the BIO CEO &...
February 3, 2022
No Comments
Unlocking the master checkpoint of cancer immunity
Our knowledge of cancer is growing daily, bringing with it new treatment strategies. As mentioned previously (here) novel immunotherapies are at the forefront of cancer research. The immune activating monoclonal…
January 28, 2022
No Comments
Three questions to Romana Gugenberger, Chief Medical and Scientific Officer
1. Despite novel immune-therapies against cancer there are still non-responders and relapses. Why is that? Romana Gugenberger: Tumors are heterogeneous. Additionally, tumors are not static but evolve. Once a response…
January 28, 2022
No Comments
